Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada
Delea TE, Amdahl J, Wang A, Amonkar MM, Thabane M
 
 
Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.
Bibliographic details
Delea TE, Amdahl J, Wang A, Amonkar MM, Thabane M. Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada. PharmacoEconomics 2014: epub
PubMedID
25488880
DOI
10.1007/s40273-014-0241-z
Indexing Status
Subject indexing assigned by CRD
MeSH
Antineoplastic Agents; Canada; Cost-Benefit Analysis; Dacarbazine; Humans; Imidazoles; Melanoma; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years
AccessionNumber
22014044541
Date bibliographic record published
12/02/2015
 
NHS Economic Evaluation Database (NHS EED)
Produced by the Centre for Reviews and Dissemination
Copyright © 2026 University of York
 
Homepage
Options
Print
PDF
 
PubMed record
Original research
 
Share
 

Message for NHS EED database users